From Vision to Trials: Seven Years of Bold Science, One Mission Taking Shape
It marks seven years since we embarked on the bold and exciting journey of developing a new generation of therapeutic oligonucleotides – medicines that, thanks to their unique mechanism of action, are widely regarded as the future of precision pharmacology. ✨
💪 Over these years, we have built state-of-the-art laboratories for organic synthesis, material characterization, molecular biology and cell biology – all essential to transform innovative oligonucleotide concepts into real, effective therapeutic candidates.
👩🔬👨⚕️ Working hand in hand with clinical institutions and external partners, we have ventured into oncology, infectious diseases and renal disorders. Our drug candidates have completed full preclinical validation and are now moving into clinical trials. Their strong clinical relevance and exceptional preclinical performance have also opened new horizons – from neurodegenerative to cardiovascular diseases – where we are developing prototypes of safe, functional therapeutics built on our patented ESiNAR-X platform. 📑
⚡️ We have aligned our operations with ISO standards to ensure the highest quality across every R&D process. And we continue to grow – as professionals and as people. Our work and innovations have earned several prestigious international awards, fueling our confidence and inspiring us to push even further. 🤞
We truly believe that high-quality science can be transformed into meaningful therapeutic solutions – solutions that ultimately serve the person who matters most: the patient. That belief is the driving force behind everything we do.
Thank you to everyone who is part of this journey. ❤️